Olsson H, Davies J R, Holst K E, Schröder U, Petersson K
Department of Endodontics, Faculty of Odontology, Malmö University, Sweden.
Int Endod J. 2005 Mar;38(3):186-94. doi: 10.1111/j.1365-2591.2004.00932.x.
To investigate the effect of Emdogain Gel (Biora AB, Malmo, Sweden), consisting of a enamel matrix derivative (EMD) in a propylene glycol alginate (PGA) vehicle, on experimentally exposed human pulps and to register postoperative symptoms.
Nine pairs of contralateral premolars scheduled for extraction on orthodontic indications were included. Following a superficial pulp amputation performed with a small (016) diamond bur, either EMDgel or a mix of calcium hydroxide and sterile saline was placed at random in contact with the pulp wound. The subjects made records of symptoms and were also interviewed about pain/discomfort by a blinded examiner. After 12 weeks the teeth were extracted, prepared and subjected to light microscopic examination in which the inflammation and newly formed hard tissue in the pulp were analysed. Immunohistochemistry was performed using affinity-purified rabbit anti-EMD polyclonal antibodies.
Postoperative symptoms were less frequent in the EMDgel-treated than in the calcium hydroxide-treated teeth, especially during the first six weeks. In the EMDgel-treated teeth, new tissue partly filled the space initially occupied by the gel and hard tissue was formed alongside the exposed dentine surfaces and in patches in the adjacent pulp tissue. EMD was detected in the areas where new hard tissue had been formed. The wound area of the EMDgel-treated teeth exhibited inflammation in the majority of the teeth whereas less inflammation was seen in the calcium hydroxide-treated teeth where the hard tissue was formed as a bridge.
In the EMDgel-treated teeth, postoperative symptoms were less frequent and the amount and pattern of hard tissue formation were markedly different than in the teeth treated with calcium hydroxide. However, the operative procedure and the formulation with EMD in a PGA vehicle do not seem to be effective for the formation of a hard tissue barrier.
研究由牙釉质基质衍生物(EMD)与藻酸丙二醇酯(PGA)载体组成的Emdogain凝胶(瑞典马尔默市Biora AB公司)对实验性暴露的人牙髓的影响,并记录术后症状。
纳入9对因正畸需要而计划拔除的对侧前磨牙。用小(016)金刚石车针进行浅表牙髓切断术后,将EMD凝胶或氢氧化钙与无菌盐水的混合物随机放置在与牙髓创面接触的位置。受试者记录症状,并且由一位不知情的检查者就疼痛/不适情况对他们进行访谈。12周后拔除牙齿,进行制备并进行光镜检查,分析牙髓中的炎症和新形成的硬组织。使用亲和纯化的兔抗EMD多克隆抗体进行免疫组织化学检测。
与氢氧化钙治疗组牙齿相比,EMD凝胶治疗组牙齿术后症状出现的频率较低,尤其是在最初的六周内。在EMD凝胶治疗的牙齿中,新组织部分填充了最初被凝胶占据的空间,并且在暴露的牙本质表面旁边以及相邻牙髓组织的斑块中形成了硬组织。在新形成硬组织的区域检测到了EMD。EMD凝胶治疗组牙齿的创面区域在大多数牙齿中表现出炎症,而在氢氧化钙治疗组牙齿中炎症较少,硬组织形成了桥接。
与氢氧化钙治疗的牙齿相比,EMD凝胶治疗的牙齿术后症状出现频率较低,硬组织形成的数量和模式也明显不同。然而,手术操作以及PGA载体中含EMD的制剂似乎对形成硬组织屏障无效。